ÂÜÀòÂÒÂ×

Naseem Amin is an accomplished professional with extensive experience in the pharmaceutical and biotechnology sectors. Currently serving as a Member of the Board of Directors at Avadel Pharmaceuticals plc since May 2024, Amin is also the Chief Executive Officer and Board Member at Orphalan, a position held since October 2017. Additionally, involvement with various organizations includes roles as a Member of the Board of Trustees at the Pakistan Education Foundation and The British Pakistan Foundation, both since 2019 and January 2015 respectively. Amin previously held significant positions such as Chairman and Non-Executive Director at Bellerophon Therapeutics until May 2024, Executive Chairman at Arix Bioscience plc from April 2020 to April 2021, and Venture Partner at Advent Life Sciences LLP from January 2015 to April 2020. Earlier career highlights include serving as Chief Scientific Officer at Smith & Nephew Plc and SVP Business Development at Biogen Idec. Educational qualifications include an MBA from Northwestern University's Kellogg School of Management and MBBS and BSc degrees from University College London.